Its leading investigational drug demonstrated relatively high levels of weight loss in a late-stage clinical trial.
Zacks Investment Research on MSN
NVO vs. VKTX: Which obesity stock could deliver bigger gains?
Novo Nordisk NVO and Viking Therapeutics VKTX both operate in the obesity-treatment market. Novo Nordisk is recognized as a leader in the GLP-1 treatment space, marketing its semaglutide drugs under ...
Novo Nordisk enters the final stretch of 2026 with a regulatory and clinical calendar that is unusually crowded — and ...
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of ...
Amy Schumer showed off her floral swimsuit and scuba diving adventure in Turks and Caicos, calling her PADI certification one ...
Regeneron Pharmaceuticals, Inc. Q3 earnings preview: click for how Dupixent growth, positive Phase 3 results, and a ...
A real-world study of 194 patients found those who switched to the daily pill lost an average of 8.8 pounds over 3 months ...
GLP-1 ads are everywhere, but they say little about training. SWEAT DC’s Gerard Burley, who takes one himself, says gyms need ...
In the Eli Lilly clinical trial, retatrutide was administered by injection. GLP-1 drugs can also be administered by injection ...
Hims & Hers Health (HIMS) is positioned as a dominant DTC Telehealth platform leveraging GLP-1s to create frictionless, ...
Key Stats for Eli Lilly StockPrice change for Eli Lilly stock in the last 6 months: 37%$LLY Stock Price as of Oct. 17: $125752-Week High: $1293$LLY Stock Price Target: $1328What Happened?The European ...
Healio Gastroenterology and its collaborators unveiled the newest class of Disruptive Innovators Award recipients during the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results